Evidence map›Paper›PMID 32449736›Full record

ArticleJournal of visualized experiments : JoVE2020

In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish.

Xiaodan Qin, Fabrice F J Laroche, Saquib Ahmed M A Peerzade, Andrew Lam, Igor Sokolov, Hui Feng

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Long-Term Cell-Membrane-Coated Ultrabright Nanospheres for Targeted Cancer Cell Imaging and Hydrophobic Drug Delivery.Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
  2. Article
  3. Review
  4. Zebrafish as a Model for Anticancer Nanomedicine Studies.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaodan Qin *Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Research Center, Boston University School of Medicine.
Fabrice F J Laroche *Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Research Center, Boston University School of Medicine.
Saquib Ahmed M A PeerzadeDepartment of Biomedical Engineering, Tufts University.
Andrew LamDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Research Center, Boston University School of Medicine.
Igor SokolovDepartment of Biomedical Engineering, Tufts University; Department of Mechanical Engineering, Tufts University; Department of Physics, Tufts University.
Hui FengDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Research Center, Boston University School of Medicine; huifeng@bu.edu.

Funding

The Role of DLST in LeukemogenesisR01CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2018 to 2022
$2.0M
"Oncorequisite" Genes in MYC-mediated TransformationR00CA134743 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2012 to 2014
$712k
The Role of DLST in LeukemogenesisR56CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2017 to 2017
$376k
"Oncorequisite" Genes in MYC-mediated TransformationK99CA134743 · NCI · DANA-FARBER CANCER INST · PI FENG, HUI · 2009 to 2010
$282k
Star-dots fluorescent nanoparticles for flow cytometry and biomedical imagingR41AI142890 · NIAID · NANOSCIENCE SOLUTIONS, LLC · PI SOKOLOV, IGOR · 2019 to 2019
$150k
NCI NIH HHS K99 CA134743NCI NIH HHS R00 CA134743NCI NIH HHS R01 CA215059NCI NIH HHS R56 CA215059NIAID NIH HHS R41 AI142890
6 · The paper itself

Abstract

Developing nanoparticles capable of detecting, targeting, and destroying cancer cells is of great interest in the field of nanomedicine. In vivo animal models are required for bridging the nanotechnology to its biomedical application. The mouse represents the traditional animal model for preclinical testing; however, mice are relatively expensive to keep and have long experimental cycles due to the limited progeny from each mother. The zebrafish has emerged as a powerful model system for developmental and biomedical research, including cancer research. In particular, due to its optical transparency and rapid development, zebrafish embryos are well suited for real-time in vivo monitoring of the behavior of cancer cells and their interactions with their microenvironment. This method was developed to sequentially introduce human cancer cells and functionalized nanoparticles in transparent Casper zebrafish embryos and monitor in vivo recognition and targeting of the cancer cells by nanoparticles in real time. This optimized protocol shows that fluorescently labeled nanoparticles, which are functionalized with folate groups, can specifically recognize and target metastatic human cervical epithelial cancer cells labeled with a different fluorochrome. The recognition and targeting process can occur as early as 30 min postinjection of the nanoparticles tested. The whole experiment only requires the breeding of a few pairs of adult fish and takes less than 4 days to complete. Moreover, zebrafish embryos lack a functional adaptive immune system, allowing the engraftment of a wide range of human cancer cells. Hence, the utility of the protocol described here enables the testing of nanoparticles on various types of human cancer cells, facilitating the selection of optimal nanoparticles in each specific cancer context for future testing in mammals and the clinic.

Indexed as

AnimalsDisease Models, AnimalHeterograftsHumansNanoparticlesNeoplasmsSilicon DioxideTumor MicroenvironmentZebrafishSilicon Dioxide

Identifiers

PMID32449736
PMCPMC7694440

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.